Wyss brings extensive technology leadership experience to advance Bioscope’s clinical AI offering
CARMEL, IN / ACCESS Newswire / March 23, 2026 / Bioscope.AI, a pioneer in clinical AI-powered medicine solutions, today announced the appointment of Felix Wyss as Chief Technology Officer.
“Felix has such a depth of technology and development experience, having led several highly successful teams for decades” said Dr. Donald E. Brown, Founder and CEO of Bioscope.AI. “As we realize the vision of Bioscope, providing physicians with extensive omics-based information that can then be turned into actionable insights using the Bioscope clinical AI companion, Felix brings more than just deep architectural knowledge, but the leadership to empower our engineering teams to deliver best-in-class results. “
Felix Wyss joins Bioscope following his tenure as VP of Technology Strategy at Glia, having previously held senior leadership roles at Genesys and Interactive Intelligence. A constant innovator holding 44 patents, Wyss combines a high-level architectural vision with a deep understanding of the granular details of high-performance real-time processing. He brings a proven track record of successfully translating complex AI R&D into seamless, highly scalable cloud platforms. He earned a master’s degree in artificial intelligence from the University of Edinburgh and a bachelor’s degree in electrical engineering from Bern University of Applied Sciences in Switzerland.
“I’m passionate about leading interdisciplinary teams with deep expertise to build secure, reliable systems that provide a delightful user experience,” said Wyss. “Physicians have long been frustrated by disjointed platforms that either lack critical patient data or cause information overload. By leveraging the latest AI and in-house innovation, we can merge rich omics data with cutting-edge medical research to generate actionable clinical insights. Don Brown has assembled a remarkably talented team of medical professionals, scientists, and AI engineers, and I’m thrilled to add my experience to the group.”
Bioscope.AI is a pioneer in AI-powered omics medicine. The company leverages artificial intelligence, genomics, and advanced diagnostics to help physicians prevent disease rather than simply treat it. When disease does occur, Bioscope enables earlier detection and clearer clinical insight, empowering physicians to help patients live longer, healthier lives. To learn more, visit http://www.bioscope.ai Press inquires contact Joe Staples – [email protected]
SOURCE: Bioscope.AI
